Omeros Corp. (OMER)

16.90
0.70 4.32
NASDAQ : Health Technology
Prev Close 16.20
Open 16.22
Day Low/High 16.22 / 16.91
52 Wk Low/High 10.30 / 27.00
Volume 125.22K
Avg Volume 428.60K
Exchange NASDAQ
Shares Outstanding 49.06M
Market Cap 831.53M
EPS -2.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Omeros Corporation Reports First Quarter 2019 Financial Results

Omeros Corporation Reports First Quarter 2019 Financial Results

Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation,...

Clinical Study Showing Reduced Incidence Of Cystoid Macular Edema With OMIDRIA® Presented At American Society Of Cataract And Refractive Surgery Annual Meeting

Clinical Study Showing Reduced Incidence Of Cystoid Macular Edema With OMIDRIA® Presented At American Society Of Cataract And Refractive Surgery Annual Meeting

Omeros Corporation (Nasdaq: OMER) today announced the results of a real-world clinical study showing that its FDA-approved ophthalmic drug OMIDRIA ® (phenylephrine and ketorolac intraocular solution) 1% / 0.

Omeros Corporation To Announce First Quarter 2019 Financial Results On May 9, 2019

Omeros Corporation To Announce First Quarter 2019 Financial Results On May 9, 2019

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter 2019 financial results for the period ended March 31, 2019, on Thursday, May 9, 2019, after the market closes.

Omeros Corporation Announces Presentation Of OMIDRIA® Real-World Data At Upcoming American Society Of Cataract And Refractive Surgery Annual Meeting

Omeros Corporation Announces Presentation Of OMIDRIA® Real-World Data At Upcoming American Society Of Cataract And Refractive Surgery Annual Meeting

Omeros Corporation (Nasdaq: OMER) today announced that the results of an investigator-sponsored real-world study of its FDA-approved ophthalmic drug OMIDRIA ® (phenylephrine and ketorolac intraocular solution) 1% / 0.

First Week Of OMER April 18th Options Trading

First Week Of OMER April 18th Options Trading

Investors in Omeros Corp saw new options become available this week, for the April 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the OMER options chain for the new April 18th contracts and identified one put and one call contract of particular interest.

Omeros Corporation Announces EBMT Case Report Of Resolution Of Gastrointestinal Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Following Narsoplimab Treatment

Omeros Corporation Announces EBMT Case Report Of Resolution Of Gastrointestinal Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Following Narsoplimab Treatment

Omeros Corporation (Nasdaq: OMER) today announced the recent presentation of a case report describing resolution of gastrointestinal hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) following narsoplimab treatment under...

OMER Crosses Above Key Moving Average Level

OMER Crosses Above Key Moving Average Level

In trading on Tuesday, shares of Omeros Corp crossed above their 200 day moving average of $17.16, changing hands as high as $17.42 per share. Omeros Corp shares are currently trading up about 3.5% on the day.

Omeros Corporation Announces Upcoming Educational Event At The Annual Meeting Of The European Society Of Blood And Marrow Transplantation

Omeros Corporation Announces Upcoming Educational Event At The Annual Meeting Of The European Society Of Blood And Marrow Transplantation

Omeros Corporation (Nasdaq: OMER) today announced an upcoming educational event at the 2019 Annual Meeting of the European Society of Blood and Marrow Transplantation to be held in Frankfurt, Germany on March 24-27, 2019.

Omeros Corporation Reports Fourth Quarter And Year-End 2018 Financial Results

Omeros Corporation Reports Fourth Quarter And Year-End 2018 Financial Results

Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation,...

Omeros Corporation To Announce Fourth Quarter And Year-End 2018 Financial Results On March 1, 2019

Omeros Corporation To Announce Fourth Quarter And Year-End 2018 Financial Results On March 1, 2019

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end 2018 financial results for the period ended December 31, 2018, on Friday, March 1, 2019, before the market opens.

Omeros Corporation Announces USAN And INN Selection Of Nonproprietary Name For OMS721

Omeros Corporation Announces USAN And INN Selection Of Nonproprietary Name For OMS721

Omeros Corporation (Nasdaq: OMER) today announced that, as the company prepares for planned commercialization of OMS721, the United States Adopted Names (USAN) Council, in consultation with the World Health Organization's International Nonproprietary...

Notable Thursday Option Activity: OMER, DLR, OSTK

Notable Thursday Option Activity: OMER, DLR, OSTK

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Omeros Corp , where a total of 2,902 contracts have traded so far, representing approximately 290,200 underlying shares. That amounts to about 60.7% of OMER's average daily trading volume over the past month of 478,220 shares.

Omeros Corporation Streamlines Path To Biologics License Application For OMS721 In HSCT-TMA Following Meeting With FDA

Omeros Corporation Streamlines Path To Biologics License Application For OMS721 In HSCT-TMA Following Meeting With FDA

Omeros Corporation (Nasdaq: OMER) today announced that, based on a recent meeting with the U.

Omeros Corporation Appoints Thomas F. Bumol, Ph.D., To Board Of Directors

Omeros Corporation Appoints Thomas F. Bumol, Ph.D., To Board Of Directors

Omeros Corporation (NASDAQ: OMER) today announced the appointment of Thomas F. Bumol, Ph.

Omeros Finalizes With FDA Clinical Plan For OMS721 Approval In IgA Nephropathy

Omeros Finalizes With FDA Clinical Plan For OMS721 Approval In IgA Nephropathy

Omeros Corporation (Nasdaq: OMER) today announced that it has finalized its clinical plan for OMS721 submission and approval in immunoglobulin A nephropathy (IgAN) following a recent meeting with the U.

Omeros Corporation Announces Record High Quarterly Revenue Results For The Fourth Quarter 2018

Omeros Corporation Announces Record High Quarterly Revenue Results For The Fourth Quarter 2018

Omeros Corporation (Nasdaq: OMER), today announced unaudited preliminary revenue results for the fourth quarter ended December 31, 2018.

First Week Of OMER August 16th Options Trading

First Week Of OMER August 16th Options Trading

Investors in Omeros Corp saw new options become available this week, for the August 16th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 221 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Omeros Becomes Oversold (OMER)

Omeros Becomes Oversold (OMER)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Noteworthy Thursday Option Activity: OMER, PTLA, BGS

Noteworthy Thursday Option Activity: OMER, PTLA, BGS

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Omeros Corp , where a total of 6,181 contracts have traded so far, representing approximately 618,100 underlying shares. That amounts to about 103% of OMER's average daily trading volume over the past month of 600,365 shares.

Omeros Establishes Independent Academic Leadership Committee For Its OMS721 Phase 3 Clinical Program In IgA Nephropathy

Omeros Establishes Independent Academic Leadership Committee For Its OMS721 Phase 3 Clinical Program In IgA Nephropathy

Omeros Corporation (Nasdaq: OMER) announced today the formation of an independent Academic Leadership Committee (ALC) to support its Phase 3 clinical program for OMS721 in immunoglobulin A (IgA) nephropathy.

Omeros Announces Research Collaboration With University Of Cambridge

Omeros Announces Research Collaboration With University Of Cambridge

Omeros Corporation (Nasdaq: OMER) today announced that it has entered into a research collaboration with the University of Cambridge, establishing the Omeros Center at Cambridge for Complement and Inflammation Research (OC3IR).

Omeros Announces Clinical Strategy To Accelerate Pediatric Development Of OMS721 For The Treatment Of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)

Omeros Announces Clinical Strategy To Accelerate Pediatric Development Of OMS721 For The Treatment Of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)

Omeros Corporation (Nasdaq: OMER) today announced that it has submitted a pediatric investigational plan (PIP) for the use of OMS721 for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) to the European...

Omeros Announces Additions To Senior Management Team

Omeros Announces Additions To Senior Management Team

Omeros Corporation (Nasdaq: OMER) today announced that it hired two new senior management team members - Daniel Kirby as vice president and head of commercial and Justin McCue, Ph.

Omeros Announces Pricing Of $210 Million Offering Of Convertible Senior Notes Due 2023

Omeros Announces Pricing Of $210 Million Offering Of Convertible Senior Notes Due 2023

Omeros Corporation (Nasdaq: OMER) ("Omeros") today announced the pricing of an offering of $210 million aggregate principal amount of its 6.

Omeros Corporation Reports Third Quarter 2018 Financial Results

Omeros Corporation Reports Third Quarter 2018 Financial Results

Omeros Corporation (NASDAQ: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2018, which include: 3Q 2018 total and OMIDRIA ® revenues were $4.

Omeros Corporation To Announce Third Quarter 2018 Financial Results On November 9, 2018

Omeros Corporation To Announce Third Quarter 2018 Financial Results On November 9, 2018

Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter 2018 financial results for the period ended September 30, 2018, on Friday, November 9, 2018, before the market opens.

Reflecting on 9/11: Cramer's 'Mad Money' Recap (Tuesday 9/11/18)

Reflecting on 9/11: Cramer's 'Mad Money' Recap (Tuesday 9/11/18)

Jim Cramer says he believes we are today better prepared for both the terror and the financial attacks that America endured on 9/11.

Cypress Semiconductor, Omeros, Zuora: 'Mad Money' Lightning Round

Cypress Semiconductor, Omeros, Zuora: 'Mad Money' Lightning Round

Jim Cramer weighs in on Cypress Semiconductor, Omeros, Zuora, Kemet, Leidos, Raytheon, and Skyworks Solutions.

TheStreet Quant Rating: D- (Sell)